Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experience and review of literature

BACKGROUND: Prognosis of patients with pancreatic cancer is still extremely poor. First-line palliative therapies with FOLFIRINOX or gemcitabine/nab-paclitaxel have been established in the last decade. In the second-line, 5-FU/LV in combination with nanoliposomal irinotecan (nal-IRI) after gemcitabi...

Descripción completa

Detalles Bibliográficos
Autores principales: Möhring, Christian, Frontado Graffe, Freddy José, Bartels, Alexandra, Sadeghlar, Farsaneh, Zhou, Taotao, Mahn, Robert, Marinova, Milka, Feldmann, Georg, Brossart, Peter, Glowka, Tim R., Kalff, Jörg C., Strassburg, Christian P., Gonzalez-Carmona, Maria A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007927/
https://www.ncbi.nlm.nih.gov/pubmed/36915455
http://dx.doi.org/10.21037/jgo-22-632

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007927/
https://www.ncbi.nlm.nih.gov/pubmed/36915455
http://dx.doi.org/10.21037/jgo-22-632

Ejemplares similares